Extramedullary disease in myeloma: updates from ASH 2020 скачать в хорошем качестве

Extramedullary disease in myeloma: updates from ASH 2020

Meral Beksac, MD, Ankara University, Ankara, Turkey, provides an update from the virtual ASH meeting on extramedullary disease in multiple myeloma. Dr Beksac shares the results of a subgroup analysis of the Phase III safety and efficacy trial (NCT02990338) of isatuximab-pomalidomide-dexamethasone (Isa-Pd) compared with Pd alone in patients with relapsed/refractory multiple myeloma and soft-tissue plasmacytomas. This subgroup analysis agrees with findings in relapsed/refractory myeloma, that Isa-Pd significantly improves survival compared to Pd alone, with manageable side effects. Furthermore, Dr Beksac highlights similar studies evaluating extramedullary disease presented at this year's ASH meeting and compares the progression-free reached in these clinical studies, as well as CAR T-cell therapy approaches in this patient population. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.